# National Cancer Centre Japan

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/national-cancer-centre-japan/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 68.7 |
| Citations | 951,915 |
| City | Tokyo |
| Country | JP |
| Description | National Cancer Centre Japan is a research organisation in Tokyo, JP. OpenAlex records 6,695 works and 951,915 citations for it. 1,254 researchers list it as their most recent affiliation. |
| Homepage | http://www.ncc.go.jp/en/ |
| OpenAlex ID | https://openalex.org/I4210087348 |
| Researchers | 1,254 |
| ROR ID | https://ror.org/0025ww868 |
| Type | healthcare |
| Works | 6,695 |

## University papers

Showing 12 of 71.

- [Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma](https://scholariq.org/papers/gefitinib-or-carboplatin-paclitaxel-in-pulmonary-adenocarcinoma/)
- [Everolimus for Advanced Pancreatic Neuroendocrine Tumors](https://scholariq.org/papers/everolimus-for-advanced-pancreatic-neuroendocrine-tumors/)
- [Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer](https://scholariq.org/papers/japanese-society-for-cancer-of-the-colon-and-rectum-jsccr-guidelines-2016-for/)
- [Comprehensive genomic profiles of small cell lung cancer](https://scholariq.org/papers/comprehensive-genomic-profiles-of-small-cell-lung-cancer/)
- [Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer](https://scholariq.org/papers/japanese-society-for-cancer-of-the-colon-and-rectum-jsccr-guidelines-2019-for/)
- [Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-after-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma/)
- [2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial](https://scholariq.org/papers/2-year-follow-up-of-trastuzumab-after-adjuvant-chemotherapy-in-her2-positive/)
- [Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer](https://scholariq.org/papers/metagenomic-and-metabolomic-analyses-reveal-distinct-stage-specific-phenotypes/)
- [Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort](https://scholariq.org/papers/neoadjuvant-chemotherapy-with-trastuzumab-followed-by-adjuvant-trastuzumab/)
- [Identification of Genes Upregulated in <i>ALK</i> -Positive and <i>EGFR/KRAS/ALK</i> -Negative Lung Adenocarcinomas](https://scholariq.org/papers/identification-of-genes-upregulated-in-i-alk-i-positive-and-i-egfr-kras-alk-i/)
- [Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators](https://scholariq.org/papers/whole-genome-sequencing-of-liver-cancers-identifies-etiological-influences-on/)
- [Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial](https://scholariq.org/papers/adoptive-immunotherapy-to-lower-postsurgical-recurrence-rates-of-hepatocellular/)

## University researchers

- [Masaaki Ito](https://scholariq.org/researchers/masaaki-ito/)
- [Takaaki Tsuchida](https://scholariq.org/researchers/takaaki-tsuchida/)

## University top topics

Showing 8 of 25.

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Sarcoma Diagnosis and Treatment](https://scholariq.org/topics/sarcoma-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.